Update on new therapeutic options for the somatopause.
During the last decade, a significant body of evidence has accumulated, indicating that the declining activity of the GH-IGF-I axis with aging might play a role in the development of frailty and in several pathological conditions commonly seen during aging, such as atherosclerosis, cardiovascular disease, and cognitive decline. GH therapy has become widely popular as antiaging therapy in order to counteract the age-related decline in muscle mass and strength and the increase in fat mass. However there are only few proven beneficial effects of GH therapy in healthy elderly subjects and its use remains highly controversial in the scientific community. In this paper we will review the current evidence related to the use of GH and/or GH-secretagogues in normal and pathological aging.
Section of Geriatrics, Department of Internal Medicine and Biomedical Sciences, School of Geriatrics, University of Parma, Italy. gpceda@unipr.it
Gian Paolo
GP
Ceda
Elisabetta
E
Dall'Aglio
Simonetta
S
Morganti
Licia
L
Denti
Marcello
M
Maggio
Fulvio
F
Lauretani
Artoni
A
Andrea
Graziano
G
Ceresini
Chiara
C
Cattabiani
Giorgio
G
Valenti
D000368:Aged; D000375:Aging / Q000378:metabolism* / Q000502:physiology; D002908:Chronic Disease; D016330:Frail Elderly; D054439:Ghrelin / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy / Q000378:metabolism; D020249:Hormone Replacement Therapy; D019382:Human Growth Hormone / Q000378:metabolism* / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007674:Kidney Diseases / Q000188:drug therapy / Q000378:metabolism; D009765:Obesity / Q000188:drug therapy / Q000378:metabolism; D013141:Spiro Compounds / Q000627:therapeutic use
D054439:Ghrelin; D007211:Indoles; D013141:Spiro Compounds; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; C094817:ibutamoren mesylate